Suppression of testicular androgenesis by D-tryptophan-6-luteinizing hormone-releasing hormone does not affect TSH secretion in male subjects.
Basal and TRH-stimulated TSH secretion was evaluated in six patients suffering from prostatic cancer, before and after antiandrogenic treatment performed using a long-acting LHRH analogue, D-Trp-6-LHRH. Although serum testosterone values dropped to minimal levels after treatment, TSH secretion remained unchanged. Observed results suggest that pharmacological castration does not affect the regulatory mechanisms involved in the control of TSH secretion.
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000096:biosynthesis*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013737:Testis / Q000187:drug effects / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood; D017329:Triptorelin Pamoate
D000726:Androgen Antagonists; D000728:Androgens; D014284:Triiodothyronine; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; D013974:Thyroxine